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Variation between Point-of-Care and Laboratory HbA1cTesting in Clinical Practice 
Abstract 
Aims: The aim of this study was to identify potential disparities between Point-Of-Care Testing (POCT) 
and laboratory hemoglobinH bA1c reporting at a Federally Qualified Health Center (FQHC). 
Methods: The electronic medical record was reviewed to identify POCT HbA1c done at a FQHC and 
centralized laboratory HbA1c performed on the same day. Manual data extraction was used to identify 
potential variables that could account for disparities between POCT and laboratory testing. 
Results: A total of 42 samples in 40 patients were identified. The median HbA1c difference was 1.5mmol/
mol (0.15%) and ranged from -26-52 mmol/mol (-2.4 to 4.8%). Of the patients in the study, two had 
underlying co morbidities that could affect the POCT HbA1c. 
Conclusion: Point-of-care HbA1c testing should not be used in solidarity to diagnosis pre-diabetes and 
diabetes. When using HbA1c results to guide therapy, self-monitoring of blood glucose and symptoms of 
both hypo- and hyperglycemia should be correlated to help determine appropriate therapy. 
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Introduction
HbA1c is recommended for screening, diagnosis, and monitoring diabetes [1-2].Point-of-care 
testing in the primary care setting has increased the number of documented HbA1c since the 
patient medical record for between allowing and providers to make preventative or therapeutic 
interventions[3]. However, disparities between POCT HbA1c and laboratory measurements in a 
controlled environment have been reported to be as high as 5 mmol/mol (0.4%) [4-5]. The impact of 
this may result in misdiagnosis and/or overly aggressive treatment increasing the risk for medication 
adverse effects. The American Diabetes Association recommends that if POCT is used for diagnostic 
purposes, the results should be confirmed by repeat testing unless the patient is experiencing overt 
signs of hyperglycemia[2].Since use of POCT HbA1c began at this FQHC in 2011, several providers 
noticed disparities between testing performed onsite and laboratory. The purpose of this paper was 
to identify any HbA1c variances in a real world setting between POCT and laboratory testing. 
Methods
Design
This is a retrospective review of the electronic medical record. Point-of-care HbA1c testing 
with DCATM Vantage (Siemens Healthcare Diagnostics) began in May 2011. Reagent cartridges are 
stored and calibrated after each new lot number is received per manufacturer specifications. Three 
of our nine practice sites utilize on site POCT HbA1c. Each utilizes the same equipment, policies 
and procedures to ensure ongoing quality control. A report from May 2011 through May 2016 was 
created to identify patients who had both POCT and central laboratory HbA1cs performed on the 
same day. Any patients that had a POCT HbA1c performed at one of the three locations that use 
onsite testing were eligible for inclusion. Results were excluded if both onsite and central laboratory 
tests were not performed on the same day. This study was Institutional Review Board approved.
Sample 
Our center is a FQHC. It provides a broad range of health services to the area’s inner city 
communities. Approximately 15% of the 750,000 residents in our county live below the poverty 
level. Additionally, our practice site provides care to a large number of refugee patients from several 
continents.
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Abstract
Aims: The aim of this study was to identify potential disparities between Point-Of-Care Testing 
(POCT) and laboratory hemoglobinH bA1c reporting at a Federally Qualified Health Center 
(FQHC).
Methods: The electronic medical record was reviewed to identify POCT HbA1c done at a FQHC 
and centralized laboratory HbA1c performed on the same day. Manual data extraction was used to 
identify potential variables that could account for disparities between POCT and laboratory testing.
Results: A total of 42 samples in 40 patients were identified. The median HbA1c difference was 
1.5mmol/mol (0.15%) and ranged from -26-52 mmol/mol (-2.4 to 4.8%). Of the patients in the 
study, two had underlying co morbidities that could affect the POCT HbA1c.
Conclusion: Point-of-care HbA1c testing should not be used in solidarity to diagnosis pre-diabetes 
and diabetes. When using HbA1c results to guide therapy, self-monitoring of blood glucose and 
symptoms of both hypo- and hyperglycemia should be correlated to help determine appropriate 
therapy.
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Data analysis
Descriptive statistics were used to analyze the information 
gathered from the medical record. Point-of-care testing HbA1c 
results +/-5 mmol/mol (0.5%) from centralized laboratory results 
are considered clinically significant differences based on previous 
publications.[6] Patient records for these charts were reviewed 
manually to identify variables that are known to influence POCT 
HbA1c testing.[7] Evaluation of POCT technique in the pre- and post-
analytic phases was not available.
Results
A total of 42 POCT HbA1cs were performed on the same day 
(Figure. 1). Fourteen samples showed a clinical significant difference 
of >5 mmol/mol (0.5%) ranging from -26-52 mmol/mol (-2.4 to 
4.8%) (Table 1).The median difference was 1.5 mmol/mol (0.15%). 
The most significant changes were observed in patients with HbA1c 
laboratory values above 86 mmol/mol (10%). Between the three 
different sites, the number of clinically significant differences for 
Site 1 was eight. For Sites 2 and 3 the number was four and two 
respectively. Site 1 receives roughly the same volume of patients as 
Sites 2 and 3 combined. Each clinically significant difference was 
performed at least one month apart. A total of seven different staff 
members performed the onsite testing that resulted in a clinically 
significant difference, two of whom were connected to two differences 
each. Information on staff members for five draws was not able to 
be determined due to inadequate documentation. Two patients each 
had their blood drawn on the same day on two separate occasions. 
Neither resulted in a clinically significant difference between results. 
A manual chart review resulted in two patients with underlying 
comorbidities that may affect point-of-care testing according to the 
HbA1c reagent cartridge package insert[7]. Both had thalassemia. One 
patient did not have significant difference while the other resulted in 
a 7 mmol/mol (0.7%) difference, 37-44 mmol/mol (5.5-6.2%) for the 
central laboratory and point-of-care testing respectively.
Discussion
HbA1c testing in patients with diabetes is recommended quarterly 
for uncontrolled patients and at least annually for patients who are 
currently meeting their glycemic goals.[1-8]When POCT HbA1c 
testing is used for diagnostic purposes confirmation should be 
performed at a laboratory that is NGSP certified with standardized 
DCCT assays due to the potential for errors with POCT. In our 
study POCT and laboratory testing occurred on the same day 42 
times. The decision to perform both tests is not readily available as 
data was collected retrospectively. A majority of the patients already 
had confirmed diabetes and did not have a blood dyscrasia thus 
confirmatory testing was not indicated per guidelines and DCA 
Vantage specifications. Laboratory errors are well documented in the 
literature and have the potential to result in significant patient harm.
[9] A majority of errors occur in the pre- and post-analytical phase.
[10]Point-of-care-testing may be particularly prone to errors relative 
to central laboratory testing due to less stringent performance criteria 
allowed for POCT. At our center each site delegates quality assurance 
procedures to a licensed practical nurse who ensures consistency 
with policies, procedures, and manufacturer specifications. The 
LPN checks to make sure the equipment is in working order, HbA1c 
cartridges are in date, and appropriately calibrated for specific lot 
numbers. Quality assurance log books were reviewed to identify 
potential temporal relationship between machine maintenance, 
cartridge lot calibration, or any other issues that may have cause 
disparate results. None were identified. All LPNs as part of their on 
boarding process receive initial training on DCATM Vantage (Siemens 
Healthcare Diagnostics) POCT HbA1c machines and required to 
undergo an annual competency to maintain proficiency. The DCATM 
Vantage (Siemens Healthcare Diagnostics) POCT HbA1c machines 
accurately measure ranges between 4-130 mmol/mol (2.5-14%).[7]It 
does this by measuring total HbA1c concentrations in addition to total 
hemoglobin concentrations (%A1C = [A1C] / [Hgb] x 100). Factors 
that influence the lifespan of red blood cells (hemolytic anemia, 
thalassemia) can result in lower than expected HbA1c results while 
those that elevate it may falsely elevate values.[11-12] Two patients 
had thalassemia. Only one had clinical significant differences between 
results. The POCT test was 0.7% higher and cannot be explained by 
the underlying pathology as with a shorter red blood cell life span 
theHbA1c result should have been falsely low. There were several 
limitations to our study. First, collection and processing technique 
of samples for HbA1c POCT was not available. This is significant 
as laboratory errors most often occur in the pre- and post-analytic 
phases with POCT. We reviewed the electronic medical record to 
identify staff performing tests who may be routinely associated with 
discrepancies. However this data was incomplete preventing adequate 
analysis. Furthermore numerous central laboratory sites were used 




































Figure 1: Fourteen samples showed a clinical significant.






-26 (-2.4) 123 (13.4) 97 (11)
-18 (-1.6) 60 (7.6) 42 (6)
-15 (-1.3) 71 (8.6) 56 (7.3)
-10 (-0.9) 90 (10.4) 80 (9.5)
-7 (-0.7) 44 (6.2) 37 (5.5)
5 (0.5) 39 (5.7) 44 (6.2)
5 (0.5) 62 (7.8) 67 (8.3)
6 (0.6) 73 (8.8) 79 (9.4)
6 (0.6) 50 (6.7) 56 (7.3)
8 (0.7) 67 (8.3) 75 (9)
7 (0.7) 61 (7.7) 68 (8.4)
9 (0.8) 50 (6.7) 59 (7.5)
29 (2.6) 46 (6.4) 75 (9)
52 (4.8) 38 (6.5) 100 (11.3)
Table 1: Difference of >5 mmol/mol (0.5%) ranging from -26-52 mmol/mol (-2.4 
to 4.8%).
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addition the impact on patient safety is unknown. Escalation or de-
escalation of glycemic therapy and the direct impact on patients’ 
blood glucose could not be correlated due to the retrospective nature 
of our study.
Conclusion
This study highlights the potential misleading POCT HbA1c results 
in the primary care setting. Several patient specific factors are known 
to influence testing but could not fully explain our discordant results. 
In a controlled setting the DCATM Vantage (Siemens Healthcare 
Diagnostics) displays a high degree of accuracy. The standard 
deviation between POCT and control groups ranged from 0.9-1.2 
mmol/mol (0.18-0.39%) in validation studies thus onsite testing 
procedure may be the most likely reason for the different results 
noted in our study. Providers should correlate POCT HbA1c with 
clinical findings and home blood glucose testing when diagnosing 
and adjusting therapies for diabetes.
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